Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,039 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.
Suzuki C, Blomqvist L, Hatschek T, Carlsson L, Einbeigi Z, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Söderberg M, Sundqvist M, Walz TM, Aström G, Fujii H, Jacobsson H, Glimelius B. Suzuki C, et al. Among authors: fujii h. Med Oncol. 2013 Mar;30(1):415. doi: 10.1007/s12032-012-0415-5. Epub 2013 Jan 16. Med Oncol. 2013. PMID: 23322522 Clinical Trial.
Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study.
Iwata H, Fujii H, Masuda N, Mukai H, Nishimura Y, Katsura K, Ellis CE, Gagnon RC, Nakamura S. Iwata H, et al. Among authors: fujii h. Breast Cancer. 2015 Mar;22(2):192-200. doi: 10.1007/s12282-013-0475-1. Epub 2013 May 21. Breast Cancer. 2015. PMID: 23689990 Free PMC article. Clinical Trial.
Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
Nishina T, Azuma M, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Mitome T, Kageyama H, Hyodo I. Nishina T, et al. Among authors: fujii h. Gastric Cancer. 2019 Jan;22(1):138-146. doi: 10.1007/s10120-018-0845-7. Epub 2018 Jun 9. Gastric Cancer. 2019. PMID: 29948386
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.
Suzuki Y, Saeki T, Aogi K, Toi M, Fujii H, Inoue K, Watanabe T, Fujiwara Y, Ito Y, Takatsuka Y, Iwata H, Arioka H, Tokuda Y. Suzuki Y, et al. Among authors: fujii h. Int J Clin Oncol. 2013 Aug;18(4):590-7. doi: 10.1007/s10147-012-0421-9. Epub 2012 May 15. Int J Clin Oncol. 2013. PMID: 22585426 Clinical Trial.
Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin.
Nishikawa K, Yamada Y, Ishido K, Gotoh M, Bando H, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Nishikawa K, et al. Among authors: fujii h. Gastric Cancer. 2017 Jul;20(4):640-645. doi: 10.1007/s10120-016-0666-5. Epub 2016 Nov 7. Gastric Cancer. 2017. PMID: 27822684 Clinical Trial.
Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2).
Yokota T, Ota Y, Fujii H, Kodaira T, Shimokawa M, Nakashima T, Monden N, Homma A, Ueda S, Akimoto T. Yokota T, et al. Among authors: fujii h. Int J Clin Oncol. 2021 Feb;26(2):316-325. doi: 10.1007/s10147-020-01817-4. Epub 2020 Oct 30. Int J Clin Oncol. 2021. PMID: 33125596
4,039 results